MOFEBUTAZONE SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H15N2O2.Na
Molecular Weight	254.2602
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].CCCCC1=C([O-])N(NC1=O)C2=CC=CC=C2

InChI

InChIKey=JOFXNOWRCUZNRM-UHFFFAOYSA-M

InChI=1S/C13H16N2O2.Na/c1-2-3-9-11-12(16)14-15(13(11)17)10-7-5-4-6-8-10;/h4-8,17H,2-3,9H2,1H3,(H,14,16);/q;+1/p-1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3440938 | https://www.ncbi.nlm.nih.gov/pubmed/6495891 | https://www.ncbi.nlm.nih.gov/pubmed/8871264 |

Mofebutazone (or monophenylbutazone) is a 3,5-pyrazolinedione derivative study for treating asthma and muscular pain. It was found that there was no increase in the incidence or severity of the asthmatic attacks during the course of mofebutazone treatment. The drug tended to improve the tested pulmonary ventilatory functions or at least to leave them unchanged. All the mofebutazone-treated individuals showed a dramatic reduction in the concentrations of PGE2, PGF2alpha, and LTs in their BAL, but there was no consistent correlation between the extent of reduction and the degree of benefit or worsening sustained by an individual patient. Mofebutazone was found to be excreted almost exclusively via the kidney

Approval Year

PubMed

Title	Date	PubMed
Rheumatoid arthritis: comparison of treatment with monophenylbutazone and phenylbutazone.	1969-12-27	4903691
[Bilateral renal cortical necrosis following pyrazolone treatment].	1967-06-09	4225848

Name

Type

Language

MOFEBUTAZONE SODIUM

Common Name

English

3,5-PYRAZOLIDINEDIONE, 4-BUTYL-1-PHENYL-, SODIUM SALT (1:1)

Preferred Name

English

MONOPHENYLBUTAZONE SODIUM SALT

Common Name

English

Mofebutazone sodium [WHO-DD]

Common Name

English

SODIUM MOFEBUTAZONE

Common Name

English

Code System Code Type Description

PUBCHEM

154733489